A case is reported of idiopathic relapsed autoimmune hemolytic anemia successfully treated with rituximab.A 43-year-old white male patient with past medical history of Evans syndrome was found to have recurrent autoimmune hemolytic anemia. Previous treatments included steroids, splenectomy, intravenous immunoglobulin, plasmapheresis, staphylococcal Protein A immunoadsorption (Prosorba column), and chemotherapeutic agents (cytoxan and vincristine). Rituximab was given weekly at 375 mg/m2 for 4 doses.The drug was well tolerated and the patient remains in remission 9 months after completion of therapy.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Maloney D, Lopez A, White C, et al. IDEC-C2B8 (Rituximab) anti CD20 monoclonal antibody therapy in patients with relapsed low grade non-Hodgkin’s lymphoma.Blood. 1997;90:2188–2195.
Saleh M, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.Semin Oncol. 2000;27:99–103.
Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia.Leukemia. 2002;16:2092–2095.
Cohen Y, Polliack A. Sustained complete remission of chronic refractory immune thrombocytopenic purpura (ITP) of 10 years duration after only two infusions of rituximab.Hematol J. 2002;3:61–62.
Mori A, Tamaru J-I, Sumi H, Kondo H. Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy.Eur J Haematol. 2002;68:243–246.
Cohen Y, Polliack A, Zelig O, Goldfarb A. Monotherapy with rituximab induces rapid remission of recurrent cold agglutininmediated hemolytic anemia in a patient with indolent lymphoplasmacytic lymphoma.Leuk Lymphoma. 2001;42:1405–1408.
Motto DG, Williams JA, Boxer LA. Rituximab for refractory childhood autoimmune hemolytic anemia.Isr Med Assoc J. 2002;4:1006–1008.
Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B. Anti-CD20 monoclonal antibody (Rituximab) for lifethreatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus.Br J Haematol. 2002;116:465–467.
Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children.Blood. 2003;101:3857–3861.
Seipelt G, Koschmeider S, Hoelzer D. Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome.Annal Hematol. 2001;80:170–173.
About this article
Cite this article
Galor, A., O’Brien, T. Rituximab Treatment for Relapsed Autoimmune Hemolytic Anemia in Evans Syndrome. Int J Hematol 78, 335–336 (2003). https://doi.org/10.1007/BF02983558
- Immune hemolytic anemia